Ryan & Maniskas, LLP ( www.rmclasslaw.com/cases/icgn) is investigating potential claims against the board of directors of Icagen, Inc. ("Icagen" or the "Company") (NASDAQ: ICGN) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s efforts to sell Icagen to Pfizer Inc. in a transaction valued at approximately $56 million.

Our investigation concerns possible breaches of fiduciary duty and other violations of law related to the approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Icagen. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at rmaniskas@rmclasslaw.com or visit: www.rmclasslaw.com/cases/icgn.

Under the terms of the definitive agreement, Icagen’s shareholders will receive $6 in cash for each share of common stock they own.

If you own shares of Icagen and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/icgn. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com. For more information about class action cases in general, please visit our website: www.rmclasslaw.com.

Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.

Copyright Business Wire 2010

If you liked this article you might like

Icagen Stock Falls On Unusually High Volume (ICGN)

Icagen Stock Falls On Unusually High Volume (ICGN)

Icagen, MannKind: After-Hours Trading

Icagen, MannKind: After-Hours Trading

Icagen CEO Discusses Q4 2010 Results - Earnings Call Transcript

Icagen CEO Discusses Q4 2010 Results - Earnings Call Transcript

Best and Worst Drug Stocks in Q3

Best and Worst Drug Stocks in Q3

China Direct, Ironwood: Volume Movers

China Direct, Ironwood: Volume Movers